Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 76

1.

Establishment of stable cell lines for personalized melanoma cell vaccine.

Selvan SR, Carbonell DJ, Fowler AW, Beatty AR, Ravindranath MH, Dillman RO.

Melanoma Res. 2010 Aug;20(4):280-92. doi: 10.1097/CMR.0b013e3283390696.

PMID:
20375743
[PubMed - indexed for MEDLINE]
2.

[An immunocytochemical investigation of antigen expression by skin melanoma cells cultured for vaccine production].

Moiseenko VM, Danilova AB, Danilov AO, Turkevich EA, Baldueva IA, Matsko DE.

Vopr Onkol. 2008;54(3):303-14. Russian.

PMID:
18652234
[PubMed - indexed for MEDLINE]
3.

Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens.

Schadendorf D, Fichtner I, Makki A, Alijagic S, Küpper M, Mrowietz U, Henz BM.

Br J Cancer. 1996 Jul;74(2):194-9.

PMID:
8688321
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Characterization of polyvalent allogeneic vaccines.

Van Epps D.

Dev Biol (Basel). 2004;116:79-90; discussion 133-43.

PMID:
15603185
[PubMed - indexed for MEDLINE]
5.

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.

Sondak VK, Sosman JA.

Semin Cancer Biol. 2003 Dec;13(6):409-15. Review.

PMID:
15001159
[PubMed - indexed for MEDLINE]
6.

Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R.

J Clin Oncol. 2006 Nov 1;24(31):5060-9.

PMID:
17075125
[PubMed - indexed for MEDLINE]
7.

Tumor antigen expression in melanoma varies according to antigen and stage.

Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA, Cebon J.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):764-71.

PMID:
16467087
[PubMed - indexed for MEDLINE]
Free Article
8.

Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients.

Murer K, Urosevic M, Willers J, Selvam P, Laine E, Burg G, Dummer R.

Melanoma Res. 2004 Aug;14(4):257-62.

PMID:
15305155
[PubMed - indexed for MEDLINE]
9.

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.

Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E, Bartholeyns J, Goxe B, Latour N, Leroy S, Prigent D, Martiat P, Sales F, Laporte M, Bruyns C, Romet-Lemonne JL, Abastado JP, Lehmann F, Velu T.

Cancer Immunol Immunother. 2006 Jul;55(7):819-29. Epub 2005 Sep 27.

PMID:
16187085
[PubMed - indexed for MEDLINE]
10.

Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.

Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchianò A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G.

J Clin Oncol. 2002 Oct 15;20(20):4169-80. Erratum in: J Clin Oncol 2002 Dec 1;20(23):4610.

PMID:
12377960
[PubMed - indexed for MEDLINE]
11.

Comparison of melanoma antigens in whole tumor vaccine to those from IIB-MEL-J cells.

McGee JM, Patten MR, Malnar KF, Price JA 3rd, Mayes JS, Watson GH.

Cancer Biother Radiopharm. 1999 Jun;14(3):203-8.

PMID:
10850304
[PubMed - indexed for MEDLINE]
12.

Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.

Dillman RO, Nayak SK, Barth NM, DeLeon C, Schwartzberg LS, Spitler LE, Church C, O'Connor AA, Beutel LD.

Cancer Biother Radiopharm. 1998 Jun;13(3):165-76.

PMID:
10850352
[PubMed - indexed for MEDLINE]
13.

Short-term tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer.

Dillman RO, Beutel LD, De Leon C, Nayak SK.

Cancer Biother Radiopharm. 2001 Jun;16(3):205-11.

PMID:
11471485
[PubMed - indexed for MEDLINE]
14.

Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.

[No authors listed]

BioDrugs. 2003;17(1):69-72.

PMID:
12534322
[PubMed - indexed for MEDLINE]
15.

Melacine: an allogeneic melanoma tumor cell lysate vaccine.

Sosman JA, Sondak VK.

Expert Rev Vaccines. 2003 Jun;2(3):353-68. Review.

PMID:
12903801
[PubMed - indexed for MEDLINE]
16.

Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.

Schadendorf D, Paschen A, Sun Y.

Immunol Lett. 2000 Sep 15;74(1):67-74. Review.

PMID:
10996630
[PubMed - indexed for MEDLINE]
17.

Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.

Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC.

Clin Cancer Res. 2003 Feb;9(2):657-62.

PMID:
12576432
[PubMed - indexed for MEDLINE]
Free Article
18.

Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.

Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S.

Cancer Res. 1993 Mar 1;53(5):1043-50.

PMID:
8439951
[PubMed - indexed for MEDLINE]
Free Article
19.

Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes.

Labarriere N, Pandolfino MC, Raingeard D, Le Guiner S, Diez E, Le Dréan E, Dreno B, Jotereau F.

Int J Cancer. 1998 Oct 5;78(2):209-15.

PMID:
9754654
[PubMed - indexed for MEDLINE]
20.

Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.

Reynolds SR, Oratz R, Shapiro RL, Hao P, Yun Z, Fotino M, Vukmanović S, Bystryn JC.

Int J Cancer. 1997 Sep 17;72(6):972-6.

PMID:
9378560
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk